NCT01411423View on ClinicalTrials.gov

Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan

CompletedOBSERVATIONAL
Enrollment

3,305

Participants

Timeline

Start Date

April 18, 2008

Primary Completion Date

March 16, 2012

Study Completion Date

February 28, 2016

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients who have received Nexavar for unresectable or advanced RCC.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01411423 - Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan | Biotech Hunter | Biotech Hunter